$4.105
+0.09
(+2.11%)▲
Live
Insights on Anavex Life Sciences Corp.
In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 128.6%
In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 305.5%
2.92%
Downside
Day's Volatility :5.23%
Upside
2.38%
20.92%
Downside
52 Weeks Volatility :68.9%
Upside
60.67%
Period | Anavex Life Sciences Corp. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -21.33% | -1.0% | 0.0% |
6 Months | -50.98% | 9.6% | 0.0% |
1 Year | -55.68% | 11.0% | 0.0% |
3 Years | -70.38% | 18.5% | -22.6% |
Market Capitalization | 340.3M |
Book Value | $1.61 |
Earnings Per Share (EPS) | -0.5 |
PEG Ratio | 0.0 |
Wall Street Target Price | 27.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -19.63% |
Return On Equity TTM | -28.98% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | -0.5 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.52 |
EPS Estimate Next Year | -0.64 |
EPS Estimate Current Quarter | -0.11 |
EPS Estimate Next Quarter | -0.12 |
What analysts predicted
Upside of 569.91%
Sell
Neutral
Buy
Anavex Life Sciences Corp. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Anavex Life Sciences Corp. | 4.69% | -50.98% | -55.68% | -70.38% | 37.2% |
Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
Regeneron Pharmaceuticals, Inc. | 3.22% | 20.18% | 31.88% | 93.3% | 227.58% |
Novo Nordisk A/s | 8.85% | 34.38% | 71.83% | 235.07% | 463.44% |
Vertex Pharmaceuticals Incorporated | 16.81% | 34.1% | 40.6% | 123.97% | 174.53% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Anavex Life Sciences Corp. | NA | NA | 0.0 | -0.52 | -0.29 | -0.2 | NA | 1.61 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Anavex Life Sciences Corp. | Buy | $340.3M | 37.2% | NA | 0.0% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 227.58% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 463.44% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 174.53% | 29.59 | 39.46% |
State Street Corporation
BlackRock Inc
Vanguard Group Inc
Geode Capital Management, LLC
Bank of America Corp
Nwam, LLC
anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.
Organization | Anavex Life Sciences Corp. |
Employees | 40 |
CEO | Dr. Christopher U. Missling M.B.A., M.S., Ph.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$4.11
+2.11%
Keyarch Acquisition Corp
$4.11
+2.11%
Connexa Sports Technologies Inc
$4.11
+2.11%
Us Value Etf
$4.11
+2.11%
First Wave Biopharma Inc
$4.11
+2.11%
Global X Msci Next Emerging
$4.11
+2.11%
Fat Projects Acquisition Corp
$4.11
+2.11%
Goal Acquisitions Corp
$4.11
+2.11%
Capital Link Global Fintech
$4.11
+2.11%